PIPELINE
logo
青光眼
logo
待定文字
青光眼,是由于视神经病变导致的一种不可逆的神经退行性疾病,其典型的病理表现为视网膜神经节细胞进行性丢失, 是全球首位不可逆性致盲眼病1。据估计,2020年全球约有7600万青光眼患者,其中仅在我国就可达到2100万1,2。目前最常用的疗法为通 过降低和控制眼压以延缓视神经损害,然而,相当一部分的青光眼患者即使眼压得到控制,视功能损害仍然持续进展。因此,临床迫切需要 开发新作用机制的疗法来治疗和预防青光眼相关的失明。
close
MANAGEMENT TEAM
  • Eddy WuPh.D.
    Founder, Chairman and CEO
  • York Chen M.D., EMBA
    Chief Commercial Officer
  • Qing Liu M.D., Ph.D.
    Chief Medical Officer
  • Simon TsangPh.D.
    Chief Business Officer
  • Ping ChengCA/CFA
    Vice President, Finance
  • Katherine HeNYSBA
    Senior Director, Legal
ADDRESS
@1Suite 906-908, 9F, Tower II, Century Link, 1196 Century Avenue, Shanghai, China @2Suite A09, 10th Floor, Twin Towers (East), B 12 Jianguomenwai Avenue, Beijing, China @3Room 1111, 11F., OfficePlus @Prince Edward 794-802 Nathan Road, Kowloon, Hong Kong @4Suite Level 5 63 Pirie Street, Adelaide, SA 5000, Australia
SUBSCRIBE TO OUR NEWSLETTER
Subscribe

To report a potential adverse event, please refer to the contact information below:

Global: globalsafety@arcticvision.com

Mainland China: safety.cn@arcticvision.com

Hong Kong, China: safety.hk@arcticvision.com

Copyright © 2023 ARCTIC VISION HONG KONG BIOTECH LIMITED